Most Recent
Swiss pharmaceutical giant Novartis has lost its patent infringement case against Sydney-based generics company Pharmacor over a top-selling heart medication.
ASIC wants the Full Court to overturn a finding that Noumi waived privilege over a PwC report produced under a voluntary disclosure regime, arguing the regime benefits the public in making investigations more efficient.
A novel bid to appeal the $112 million Robodebt class action settlement and bring new claims off the back of damning revelations in a royal commission report faces “significant hurdles”, a judge has said.
S&P is free to pay for a Rolls-Royce defence in "Rolls-Royce litigation" that alleges the agency engaged in fraud in assigning ratings to risky financial products, a judge has said.
Herbert Smith Freehills has lured two lateral partners to bolster its projects, energy and infrastructure practice in Australia.
Ashurst has launched a new risk consultation division designed to provide end-to-end support for clients undergoing major transformations, luring three partners from competitors to head it up.
Bayer has lost its battle to protect top-selling blood thinner Xarelto from generic competition, with the Full Court finding two patents for the drug are invalid.
An environmental group has lost a court challenge to controlled burns in the state’s Strathbogie Forest, despite arguing they would destroy the habitat of the endangered Southern greater glider.
Infant formula company Care A2 has found new lawyers as trial begins in a trade mark dispute with rival a2 Milk.